Company intelligence / Profile preview
Fujifilm
Kanagawa Prefecture, Japanholdings.fujifilm.com ↗
- Ownership
- Public · 4901
- Development stage
- Other
01
Overview
Fujifilm has several products in clinical development, including FF-10502-01 (Phase 2 for Cholangiocarcinoma), FF-10832 (Phase 1/2 for various cancers), and FF-10850 (Phase 1 for Merkel cell carcinoma). They received approval for Favipiravir in Japan for SFTS treatment in June 2024[6].
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- Liposomal drug delivery systemssmall moleculesrecombinant proteinsviral vaccinesgene therapies
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Xerox Limited (formerly Rank Xerox Limited)
04
Financials
- Market cap
- $24.9B
- Total revenue
- $21.2B
- Enterprise value
- $30.9B
Beyond the preview
Go deeper on Fujifilm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fujifilm.